Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
Luca ProsperiniShalom HaggiagCarla TortorellaSimonetta GalganiClaudio GasperiniPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
Our study supports a detrimental effect of age on the safety profile of depletive DMTs, with an increased incidence of neoplasms especially over 45 years of age. We failed to demonstrate an age-related increased incidence of infections, possibly due to latency in their occurrence.